

University of Miami/Miami VAMC CFS and GWI Research Team Leaders:

Nancy Klimas, MD Center Director, Clinical core Mary Ann Fletcher, PhD Immunology/Biomarker Gordon Broderick, PhD Computational Biology University of Alberta Barry Hurwitz, PhD Autonomic Mike Antoni, PhD CBT/Stress response John Gilmore, PhD Genomics

Funding: NIH ORWH /trans-NIH CFS working group; DOD OCMR; Veterans Affairs Research Administration; CFIDS Association of America; PANDORA; private donations

MODEL OF PATHOGENESIS

Genetic Predisposition

 $\frac{1}{1}$

Triggering event / infection



Mediators (Immune, endocrine, neuroendocrine, sleep, psychosocial, viral reactivation or persistence)



CFS/ME

| Hormone | Examples of Immune Cells with Receptors | | |
|---|---|--|--|
| Gluccocorticoids | T and B-lymphocytes, neutrophils, monocytes/macrophages | | |
| Substance P | T and B-lymphocytes, eosinophils, mast cells, monocytes/macrophages | | |
| Neuropeptide Y | T-lymphocytes, monocytes/macrophages | | |
| Corticotropin Releasing Hormone | T and B-lymphocytes, mast cells, monocytes/macrophages | | |
| Prolactin | T and B-lymphocytes, granulocytes, precursor cells, monocytes/macrophages | | |
| Growth Hormone | T and B-lymphocytes, monocytes/macrophages | | |
| Catecholamines (epinephrine/norepinephrine) | T and B-lymphocytes, neutrophils, NK cells, monocytes/macrophages | | |
| Serotonin | T and B-lymphocytes, NK cells, monocytes/macrophages | | |

2005

Mediators

- The interaction between mediators is key
- We approach CFS as an illness with a homeostasis "reset" the new homeostasis set point maintains disruptions of immune, endocrine and autonomic interaction
- The immune, autonomic, and endocrine systems find a new balance and promote symptoms
- Chronic immune activation is a key component of this model.


Immune abnormalities in GWI


Immune Activation


- DR, CD26, CD 38 expression
- TH2 cytokine shift
- □ Proinflammatory cytokines expression TNF-a, IL-1, IL6


Functional defects


NK Cell dysfunction CD8 abnormalities ↓perforins, granzymes Macrophage abnormalities Antibody production


















Neuropeptide-Y (NPY) helps to regulate of a large number of physiological and pathophysiological processes.

cardiorespiratory system immune system nervous system endocrine system

| Signal molecules Plasma levels | Ctrl | GWI | EGWI - Ectrl | P value |
|-----------------------------------|-----------------|--------------|-----------------|---------|
| IL-6 | 12.60 (0.76) | 3.45 (0.23) | 9.15 | 0.00 |
| IL-10 | 10.07 (0.85) | 3.78 (0.19) | 6.29 | 0.00 |
| TNF-a | 0.05 (0.00) | 4.89 (0.19) | 4.84 | 0.00 |
| SCD26 | 2.13 (0.08) | 6.94 (0.53) | 4.81 | 0.00 |
| NPY | 7.71 (0.55) | 12.23 (0.84) | 4.52 | 0.00 |
| | | | | |

| PHA-stimulated blood culture | Ctrl | GWI | EGWI - Ectrl | P value |
|---------------------------------|--------------|--------------|-----------------|---------|
| Saliva Cortisol | 3.12 (0.15 | 6.10 (0.32) | 2.98 | 0.00 |
| IL-la | 2.12 (0.12) | 22.01 (1.68) | 19.89 | 0.00 |
| IL-5 | 3.39 (0.28) | 13.06 (0.45) | 9.67 | 0.00 |
| IL-6 | 2.19 (0.18) | 7.09 (0.46) | 4.90 | 0.00 |
| IL-10 | 11.75 (0.97) | 6.88 (0.62) | 4.87 | 0.00 |
| TNF-a | 2.00 (0.15) | 10.23 (0.43) | 8.23 | 0.00 |
| IFN-g | 10.16 (0.44) | 10.33 (0.88) | 0.16 | 0.76 |



Conclusion

- The immune abnormalities seen in GWI include immune activation, poor cytotoxic cell function, cytokine regulatory disruptions and abnormalities of neuropeptide Y and cytokines that interface with autonomic, endocrine, and neurologic mediators.
- Many of the mediators seen are strong enough to be considered as biomarkers for GWI
- Further, immune activation, pro inflammatory cytokines and factors that promote this steady state of activation and inflammation are reasonable targets for intervention.

